当前位置: 首页 >> 检索结果
3256. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency.
作者: Julie Refardt.;Cihan Atila.;Irina Chifu.;Emanuele Ferrante.;Zoran Erlic.;Juliana B Drummond.;Rita Indirli.;Roosmarijn C Drexhage.;Clara O Sailer.;Andrea Widmer.;Susan Felder.;Andrew S Powlson.;Nina Hutter.;Deborah R Vogt.;Mark Gurnell.;Beatriz S Soares.;Johannes Hofland.;Felix Beuschlein.;Martin Fassnacht.;Bettina Winzeler.;Mirjam Christ-Crain.
来源: N Engl J Med. 2023年389卷20期1877-1887页
Distinguishing between arginine vasopressin (AVP) deficiency and primary polydipsia is challenging. Hypertonic saline-stimulated copeptin has been used to diagnose AVP deficiency with high accuracy but requires close sodium monitoring. Arginine-stimulated copeptin has shown similar diagnostic accuracy but with a simpler test protocol. However, data are lacking from a head-to-head comparison between arginine-stimulated copeptin and hypertonic saline-stimulated copeptin in the diagnosis of AVP deficiency.
3257. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
作者: Randall J Bateman.;Janice Smith.;Michael C Donohue.;Paul Delmar.;Rachid Abbas.;Stephen Salloway.;Jakub Wojtowicz.;Kaj Blennow.;Tobias Bittner.;Sandra E Black.;Gregory Klein.;Mercè Boada.;Timo Grimmer.;Akira Tamaoka.;Richard J Perry.;R Scott Turner.;David Watson.;Michael Woodward.;Angeliki Thanasopoulou.;Christopher Lane.;Monika Baudler.;Nick C Fox.;Jeffrey L Cummings.;Paulo Fontoura.;Rachelle S Doody.; .
来源: N Engl J Med. 2023年389卷20期1862-1876页
Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer's disease.
3258. Improving Trauma-Informed Care in the Face of Firearm Violence.
作者: Lynquell Biggs.;Franklin Cosey-Gay.;Sonya Mathies Dinizulu.;Divontae Harper.;Jazmin King.;Athena Mitchell.;Memory Pines.;Selwyn O Rogers.;Bradley Stolbach.
来源: N Engl J Med. 2023年389卷20期e40页 3259. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
作者: Kris V Kowdley.;Christopher L Bowlus.;Cynthia Levy.;Ulus S Akarca.;Mario Reis Alvares-da-Silva.;Pietro Andreone.;Marco Arrese.;Christophe Corpechot.;Sven M Francque.;Michael A Heneghan.;Pietro Invernizzi.;David Jones.;Frederik C Kruger.;Eric Lawitz.;Marlyn J Mayo.;Mitchell L Shiffman.;Mark G Swain.;José Miguel Valera.;Victor Vargas.;John M Vierling.;Alejandra Villamil.;Carol Addy.;Julie Dietrich.;Jean-Michel Germain.;Sarah Mazain.;Dragutin Rafailovic.;Bachirou Taddé.;Benjamin Miller.;Jianfen Shu.;Claudia O Zein.;Jörn M Schattenberg.; .; .
来源: N Engl J Med. 2024年390卷9期795-805页
Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.
3260. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.
作者: Jeffrey L Carson.;Maria Mori Brooks.;Paul C Hébert.;Shaun G Goodman.;Marnie Bertolet.;Simone A Glynn.;Bernard R Chaitman.;Tabassome Simon.;Renato D Lopes.;Andrew M Goldsweig.;Andrew P DeFilippis.;J Dawn Abbott.;Brian J Potter.;Francois Martin Carrier.;Sunil V Rao.;Howard A Cooper.;Shahab Ghafghazi.;Dean A Fergusson.;William J Kostis.;Helaine Noveck.;Sarang Kim.;Meechai Tessalee.;Gregory Ducrocq.;Pedro Gabriel Melo de Barros E Silva.;Darrell J Triulzi.;Caroline Alsweiler.;Mark A Menegus.;John D Neary.;Lynn Uhl.;Jordan B Strom.;Christopher B Fordyce.;Emile Ferrari.;Johanne Silvain.;Frances O Wood.;Benoit Daneault.;Tamar S Polonsky.;Manohara Senaratne.;Etienne Puymirat.;Claire Bouleti.;Benoit Lattuca.;Harvey D White.;Sheryl F Kelsey.;P Gabriel Steg.;John H Alexander.; .
来源: N Engl J Med. 2023年389卷26期2446-2456页
A strategy of administering a transfusion only when the hemoglobin level falls below 7 or 8 g per deciliter has been widely adopted. However, patients with acute myocardial infarction may benefit from a higher hemoglobin level.
|